More convenient proteasome inhibition for improved outcomes

Affiliations

¹ Department of Medicine, Imperial College London, London, UK.
² UCL Cancer Institute, University College London, Gower Street, London, WC1E 6BT, UK. Electronic address: kwee.yong@ucl.ac.uk.

Free article

Comment

Holger W Auner et al. Lancet Oncol. 2018 Jul.

Free article

. 2018 Jul;19(7):856-858.

doi: 10.1016/S1470-2045(18)30411-X. Epub 2018 Jun 1.

¹ Department of Medicine, Imperial College London, London, UK.
² UCL Cancer Institute, University College London, Gower Street, London, WC1E 6BT, UK. Electronic address: kwee.yong@ucl.ac.uk.

No abstract available

Comment on

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Moreau P, et al. Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Lancet Oncol. 2018. PMID: 29866475 Clinical Trial.